GBP510 (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "GBP510" in German language version.

refsWebsite
Global rank German rank
2nd place
3rd place
4th place
7th place
5,225th place
2,461st place
68th place
29th place
low place
low place
536th place
1,037th place
432nd place
770th place

clinicaltrials.gov

doi.org

  • Joon Young Song et al.: Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. In: eClinicalMedicine. Band 51, 22. Juli 2022, S. 101569, doi:10.1016/j.eclinm.2022.101569, PMID 35879941, PMC 9304916 (freier Volltext) – (englisch).
  • Alexandra C. Walls et al.: Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. In: Cell. Band 183, Nr. 5, 25. November 2020, S. 1367–1382.e17, doi:10.1016/j.cell.2020.10.043, PMID 33160446, PMC 7604136 (freier Volltext) – (englisch).
  • Walls AC, Miranda MC, Schäfer A et al.: Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. In: Cell. Band 184, Nr. 21, 14. Oktober 2021, S. 5432–5447.e16, doi:10.1016/j.cell.2021.09.015, PMID 34619077, PMC 8440233 (freier Volltext).
  • Arunachalam PS, Walls AC, Golden N et al.: Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. In: Nature. Band 594, Nr. 7862, 19. April 2021, S. 253–258, doi:10.1038/s41586-021-03530-2, PMID 33873199.
  • Yunlong Cao et al.: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. In: Nature. Band 602, Nr. 7898, 24. Februar 2022, S. 657–663, doi:10.1038/s41586-021-04385-3, PMID 35016194, PMC 8866119 (freier Volltext) – (englisch).
  • Delphine Planas et al.: Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. In: Nature. Band 602, Nr. 7898, 24. Februar 2022, S. 671–675, doi:10.1038/s41586-021-04389-z, PMID 35016199 (englisch).
  • Prabhu S. Arunachalam et al.: Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine. In: Sci Transl Med. Band 14, Nr. 658, 17. August 2022, S. eabq4130, doi:10.1126/scitranslmed.abq4130, PMID 35976993 (englisch).

europa.eu

ema.europa.eu

gov.uk

koreatimes.co.kr

mfds.go.kr

nih.gov

ncbi.nlm.nih.gov

  • Joon Young Song et al.: Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. In: eClinicalMedicine. Band 51, 22. Juli 2022, S. 101569, doi:10.1016/j.eclinm.2022.101569, PMID 35879941, PMC 9304916 (freier Volltext) – (englisch).
  • Alexandra C. Walls et al.: Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. In: Cell. Band 183, Nr. 5, 25. November 2020, S. 1367–1382.e17, doi:10.1016/j.cell.2020.10.043, PMID 33160446, PMC 7604136 (freier Volltext) – (englisch).
  • Walls AC, Miranda MC, Schäfer A et al.: Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. In: Cell. Band 184, Nr. 21, 14. Oktober 2021, S. 5432–5447.e16, doi:10.1016/j.cell.2021.09.015, PMID 34619077, PMC 8440233 (freier Volltext).
  • Arunachalam PS, Walls AC, Golden N et al.: Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. In: Nature. Band 594, Nr. 7862, 19. April 2021, S. 253–258, doi:10.1038/s41586-021-03530-2, PMID 33873199.
  • Yunlong Cao et al.: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. In: Nature. Band 602, Nr. 7898, 24. Februar 2022, S. 657–663, doi:10.1038/s41586-021-04385-3, PMID 35016194, PMC 8866119 (freier Volltext) – (englisch).
  • Delphine Planas et al.: Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. In: Nature. Band 602, Nr. 7898, 24. Februar 2022, S. 671–675, doi:10.1038/s41586-021-04389-z, PMID 35016199 (englisch).
  • Prabhu S. Arunachalam et al.: Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine. In: Sci Transl Med. Band 14, Nr. 658, 17. August 2022, S. eabq4130, doi:10.1126/scitranslmed.abq4130, PMID 35976993 (englisch).